The immune system protects the body against foreign substances such as bacteria and viruses. Inflammation is the physical response to how the body naturally protects itself against infections and injury.
Regeneron has investigational product candidates progressing through all stages of human clinical trials.
The word inflammation is derived from the Latin inflammare, to set on fire. Inflammation is the physical response to how the body naturally protects itself against injury and infections, such as from bacteria and viruses.
But inflammation can also occur when the immune system inappropriately triggers an inflammatory response to the body’s own cells. Immune responses to the body’s own cells, called autoimmune disorders, involve overproduction of a class of immune system proteins called cytokines and a sub-class called interleukins. Regeneron scientists have developed several compounds that are designed to block the actions of interleukin molecules. Rilonacept is a fusion protein that binds Interleukin-1 (IL-1). Sarilumab, previously known as REGN88, is an antibody to the Interleukin 6 receptor. Dupilumab, previously known as REGN668, is an antibody to the receptors for Interleukin 4 and Interleukin 13.
This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.